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Abstract
Background: M. pneumoniae pneumonia (MP) has been reported in 10-40% of community-acquired pneumonia 
cases. We aimed to evaluate the difference of clinical features in children with MP, according to their age and chest 
radiographic patterns.
Methods: The diagnosis of MP was made by examinations at both admission and discharge and by two serologic tests: 
the indirect microparticle agglutinin assay (≥1:40) and the cold agglutinins titer (≥1:32). A total of 191 children with MP 
were grouped by age: ≤2 years of age (29 patients), 3-5 years of age (81 patients), and ≥6 years of age (81 patients). 
They were also grouped by pneumonia pattern: bronchopneumonia group (96 patients) and segmental/lobar 
pneumonia group (95 patients).
Results: Eighty-six patients (45%) were seroconverters, and the others showed increased antibody titers during 
hospitalization. Among the three age groups, the oldest children showed the longest duration of fever, highest C-
reactive protein (CRP) values, and the most severe pneumonia pattern. The patients with segmental/lobar pneumonia 
were older and had longer fever duration and lower white blood cell (WBC) and lymphocyte counts, compared with 
those with bronchopneumonia. The patient group with the most severe pulmonary lesions had the most prolonged 
fever, highest CRP, highest rate of seroconverters, and lowest lymphocyte counts. Thrombocytosis was observed in 8% 
of patients at admission, but in 33% of patients at discharge.
Conclusions: In MP, older children had more prolonged fever and more severe pulmonary lesions. The severity of 
pulmonary lesions was associated with the absence of diagnostic IgM antibodies at presentation and lymphocyte 
count. Short-term paired IgM serologic test may be mandatory for early and definitive diagnosis of MP.
Background
Mycoplasma pneumoniae (M. pneumoniae) is an impor-
tant causative organism of respiratory infections in chil-
dren and young adults. M. pneumoniae pneumonia (MP)
has been reported in 10-40% of community-acquired
pneumonia cases, and recent studies have indicated that
younger children (<5 years of age), as well as school-aged
children, are prone to M. pneumoniae infection [1-6]. In
Korea, M. pneumoniae epidemics have occurred every 3-
4 years since the 1980s; in the most recent epidemics, the
peak age was younger than that seen previously [6]. How-
ever, few studies have attempted a clinical comparison of
MP according to age [4,5].
Difficulties exist in the detection of etiologic agents,
including  M. pneumoniae for lower respiratory tract
infections in children (especially younger children) with
regard to adequate sampling of respiratory materials for
pathogen culture and polymerase chain reaction (PCR),
a n d  t h e  n e e d  f o r  p a i r e d  b l o o d  s a m p l i n g  f o r  s e r o l o g i c
tests. In addition, it is known that in some patients, the
diagnostic antibodies are not detected in the early stage
of M. pneumoniae infection [1].
Although M. pneumoniae is a small bacterium that can
induce pneumonia, the immunopathogenesis of this
agent in humans is poorly understood. Clinical and
experimental studies support the hypothesis that lung
injury in M. pneumoniae infections is associated with the
cell-mediated immunity of the host [7-10], including
temporary anergy of purified protein derivatives (PPD)
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[9] and the dramatic beneficial effect of corticosteroids
on severe MP in adults and children [7,10-13]. Therefore,
it is expected that the severity of pulmonary lesions in
MP might differ with the age of the patients, and that lab-
oratory findings might differ according to the severity of
pneumonia.
In the present study, we used two IgM serologic tests
and two examinations at admission and discharge to
characterize the clinical features, laboratory findings, and
chest radiographic findings in children with MP during a
recent epidemic in South Korea.
Methods
We retrospectively analyzed the medical records and
chest radiographic findings of 191 children with MP who
were admitted to The Catholic University of Korea, Dae-
jeon St. Mary's Hospital during a nationwide MP epi-
demic, from January 2006 through December 2007. A
total of 1,083 patients with pneumonia or lower respira-
tory tract infections were admitted during this period.
Among them, we selected patients with MP using two
IgM serologic tests: the indirect microparticle agglutinin
assay (MAA: Serodia-Myco II, Fujirebio, Japan; positive
cutoff value ≥1:40) and the cold agglutinins titer (positive
cutoff value ≥1:32). Following parental consent, both
assays and some laboratory indices were routinely per-
formed twice: once at the time of admission and once at
discharge (mean: 6.0 ± 2.1 days apart). Subjects were
selected for inclusion in the study if seroconversion was
shown on both assays during admission, or if increased
MAA-positive titers (≥4-fold) with corresponding cold
agglutinin titers (including seroconversion) were dis-
played on the second test. Patients who tested positive in
both assays at admission, but did not have increased or
decreased titers at discharge, were regarded as having
recent past infection and were excluded from the study
(38 cases). Blood culture for bacterial pathogens was per-
formed for all pneumonia patients. Nasopharyngeal aspi-
rates or sputum for viral agents (influenza viruses type A
and B, parainfluenza viruses, respiratory syncytial virus,
and adenoviruses) and PCR for M. pneumoniae were
examined in the majority of patients (129 patients).
The chest radiographic patterns at admission of
patients with MP were divided into two groups. Patients
with increased nodular densities along the bronchial
trees and/or an interstitial pattern on the unilateral or
bilateral lung fields were designated as the bronchopneu-
monia group. Patients with distinctive subsegmental, seg-
m e n t a l  o r  l o b a r  c o n s o l i d a t i o n  w e r e  d e s i g n a t e d  a s  t h e
segmental/lobar pneumonia group. The chest radio-
graphic findings were reviewed and classified indepen-
dently by two pediatricians (KY Lee and YS Youn) and
one pediatric radiologist (JC Kim).
We divided the 191 children with MP into three groups
according to age: ≤2 years of age (29 patients), 3-5 years of
age (81 patients), and ≥6 years of age (81 patients), and
into another two groups according to pneumonia pattern:
the bronchopneumonia group (96 cases) and the segmen-
tal/lobar pneumonia group (95 cases). In addition, the
children aged ≥6 years (81 patients) were classified into
three groups based on the severity of pneumonia: the
bronchopneumonia group (25 patients), the mild seg-
mental/lobar group (33 patients), and the severe segmen-
tal/lobar group (23 patients). The mild segmental/lobar
pattern was defined as having an area of consolidation in
less than one lobe without pleural effusion, while the
severe segmental/lobar pattern was defined as having an
area of consolidation over one lobe, including multiple
lobe involvement and/or any consolidation with pleural
effusion.
We also evaluated the pneumonia patients according to
diagnostic antibody status. We compared the clinical and
laboratory characteristics among the groups. The study
was approved by our Institutional Review Board.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Science for Windows version 12.0
(SPSS, Chicago, IL, USA). Continuous variables are
reported as the mean ± standard deviation. Statistical sig-
nificance was assessed using the χ2 test for categorical
variables, and the independent sample t-test, paired t-
test, and one-way analysis of variation (ANOVA) for con-
tinuous variables. A p value < 0; 0.05 was considered sta-
tistically significant.
Results
Clinical and laboratory characteristics of M. pneumoniae 
pneumonia according to age
The mean age of the subjects was 5.5 ± 3.0 years (range, 9
months-14 years), and the male-to-female ratio was 1:1.1.
The age distribution of the patients is shown in figure 1.
The patients had symptoms and signs indicative of pneu-
monia at the time of admission. All patients had a fever
(>38°C per axilla) and cough, and the majority of patients
Figure 1 Age distribution of our patients.Youn et al. BMC Pediatrics 2010, 10:48
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had abnormal breath sounds on auscultation. Of the 191
patients with MP, 86 were seroconverters (i.e., IgM-nega-
tive at admission to IgM-positive at discharge) for both
assays, and 105 seropositive patients showed increased
MAA titers (>4-fold) with corresponding cold agglutinin
titers during hospitalization. The median titers of MAA
and cold agglutinins in seroconverters at discharge were
1:160 (range, 1:40-1:2,560) and 1:32 (range, 1:16-1:512),
respectively. The median titers of both assays in seroposi-
tive patients were 1:160 (range, 1:40-1:640) and 1:16
(range, 1:1-1:512) at admission, and 1:640 (range, 1:80-
1:10,240) and 1:64 (range, 1:8-1:1,024) at discharge,
respectively. PCR assay for M. pneumoniae was per-
formed in 129 patients; 37 patients (28.7%) were positive.
No patient showed blood culture positive for bacterial
pathogens including Streptococcus pneumoniae. A viral
study performed in the same 129 patients revealed that 2
patients were co-infected with respiratory viruses (respi-
ratory syncytial virus and parainfluenza virus A). Extra-
pulmonary manifestations of M. pneumoniae were
observed as 19 cases of skin rash, 9 cases of abnormal
hepatic enzymes (AST and ALT, >2-fold of normal val-
ues), and 1 case of encephalopathy.
We observed significant differences in certain parame-
ters among the three age groups (Table 1). The total dura-
tion of fever tended to be longer, and the frequency of
segmental/lobar pneumonia was significantly higher in
patients ≥6 years of age compared with the younger
groups (69.1% vs. 40.7% vs. 20.7%, respectively, p < 0.001).
The patients who had fever lasting ≥7 days were also
more strongly affiliated with the older groups (p = 0.04).
Laboratory findings revealed that white blood cell (WBC)
count, lymphocyte differential, and platelet count were
lower in the group of patients aged ≥6 years; however, C-
reactive protein (CRP) values were higher in this group
(Table 1). Compared with at admission, at discharge the
MP patients had significantly increased levels of lympho-
cyte differential (44.3% vs. 28.8%, respectively; p = 0.001),
total IgG (921 vs. 893 mg/dL, respectively; p = 0.01) and
platelet count (371,000/μL vs. 262,000/μL, respectively; p
< 0.001) (data not shown).
Clinical and laboratory findings according to pneumonia 
pattern
The mean age of the bronchopneumonia group was 4.6 ±
2.5 years, significantly younger than that of the segmen-
tal/lobar group (6.6 ± 3.0 years; p < 0.001). The total dura-
tion of fever (p = 0.02) and the length of hospitalization (p
= 0.001) were longer in the segmental/lobar group than in
the bronchopneumonia group. Compared with the bron-
chopneumonia group, the segmental/lobar group
recorded lower WBC count (p = 0.04), absolute lympho-
cyte count (1,900 ± 1,300/μL vs. 2,700 ± 1,700/μL, respec-
tively; p < 0.001), and platelet count (p = 0.02), but higher
CRP (2.1 ± 2.3 vs. 5.1 ± 5.3 mg/dL, respectively; p < 0.001)
(Table 2).
Clinical and laboratory findings according to severity of 
pneumonia
Because patient age may be related to the severity of
pneumonia and the levels of laboratory indices (including
WBC count and differential), we analyzed the clinical and
laboratory parameters of the subgroup of 81 older chil-
dren aged ≥6 years of age. When we divided and evalu-
ated these school-aged children into three groups
according to severity of pneumonia, as previously stated,
the patients with more severe pulmonary lesions showed
higher CRP levels (p = 0.02) and a higher proportion of
seroconverters (p = 0.001, ANOVA test). The duration of
fever and absolute lymphocyte count were significantly
different between the bronchopneumonia group and the
severe segmental/lobar pneumonia group (χ2  test and
independent sample t-test) (Table 3).
Clinical and laboratory findings according to diagnostic 
antibody status
Because the proportion of seroconverters tended to be
higher in patients who had more severe pneumonia
(Tables 2 and 3), we evaluated the clinical and laboratory
findings of the subjects according to diagnostic antibody
status: those who were seroconverted (n = 86) and those
who had increased titers (n = 105). There were no differ-
ences between the two groups in clinical and laboratory
indices, except for platelet count (240,000 ± 84,000/μL vs.
289,000 ± 90,000/μL, respectively; p < 0.001) (data not
shown).
Discussion
The epidemiologic characteristics of M. pneumoniae may
differ among populations [8]. Although earlier studies in
Western populations reported that the incidence of MP is
greatest among school-aged children [1], the age distribu-
t i o n  o f  a l l  p a t i e n t s  w i t h  M P  i n  t h e  p r e s e n t  s t u d y  w a s
between 9 months and 14 years, with peak incidence at 4-
6 years of age (figure 1). We found that MP affects chil-
dren of all age groups, whereas the clinical phenotype of
MP differs with age. Compared with the younger chil-
dren, the older children had a more severe clinical course,
manifested by longer total duration of fever, higher CRP,
and a more severe pneumonia pattern. Recent clinical
studies have also reported that some clinical features dif-
fer between younger children (≤5 years of age) and older
children (>6 years of age) [4,5]. Clinical features such as
tachypnea, upper respiratory symptoms (coryza), and
gastrointestinal symptoms (diarrhea and vomiting) were
shown to be more common in younger children [4,5], and
the rate of chest radiographic consolidation was higher in
older children [5].Youn et al. BMC Pediatrics 2010, 10:48
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Although variation in WBC count is known to be a
nonspecific finding in M. pneumonia infections, we
found that lymphopenia may be one of the characteristics
of MP in the acute stage. The mean WBC counts of chil-
dren with MP at presentation were similar to the normal
values for same-age references [14]; however, lymphocyte
differential and absolute lymphocyte counts were
decreased. In addition, the severity of MP tended to be
inversely associated with lymphocyte counts. Studies of
adult patients with MP also indicated constant leukope-
nia with lymphopenia [10,15,16].
Recent clinical studies reported that thrombocytosis
was observed in some patients with MP [4,5]. We also
f o u n d  t h a t  t h e  p l a t e l e t  c o u n t s  o f  p a t i e n t s  w i t h  M P
increased significantly in the convalescent stage, with
thrombocytosis (>400,000/μL) observed in 8% of patients
at admission but in 33% of patients at discharge. Thus,
the degree of platelet counts in MP may be associated
with the stage of inflammation and age of the patient.
Although this finding may be an epiphenomenon that fol-
lows various infections, it is not yet known whether the
phenomenon is also observed in viral or other pathogen-
induced pneumonias.
Approximately 45% of patients in the present study
were seroconverters. This finding verified the observa-
tion that many patients are IgM sero-negative at presen-
tation with MP. Absence of diagnostic IgM antibodies in
the early stage of systemic infections has been well docu-
mented in previous studies of adults and children with
MP [17,18] and other infections, including severe acute
respiratory syndrome (SARS) due to coronavirus and
measles [19,20]. Ozaki et al. reported that 31.8% of chil-
dren with MP were IgM-positive at admission when
tested using an EIA (ImmunoCard), but that 88.6% of
patients were IgM-positive when tested using paired sera
(mean of 8.0 ± 3.0 days apart) [18]. With these findings,
because some patients may be false-positives (recent past
infection), especially in younger children who may be res-
Table 1: Clinical and laboratory findings according to age
Age groups ≤2 y 3-5 y ≥6 y P
(n = 29) (n = 81) (n = 81)
Clinical characteristics
Age (y) 2.0 ± 0.7 4.2 ± 0.8 8.3 ± 2.3 <0.001
Duration of fever (d)
Before admission 3.1 ± 2.3 3.6 ± 2.8 4.2 ± 2.3 0.09
Total duration 4.8 ± 2.9 5.4 ± 3.3 6.1 ± 2.9* 0.1
Cases of ≥7 d (n,%) † 9 (31) 29 (36) 40 (49) 0.04
Hospitalization (d) 6.9 ± 1.8 6.9 ± 2.3 6.8 ± 2.1 0.9
Pneumonia (n,%)
Bronchopneumonia 23 (79) 48 (59) 25 (31) <0.001
Segmental/lobar 6 (21) 33 (41) 56 (69) <0.001
Laboratory findings
Hemoglobin (g/dL) 12.2 ± 0.9 12.1 ± 0.9 12.3 ± 0.9 0.6
Leukocyte (×103//μL) 11.2 ± 7.3 7.9 ± 3.5 7.1 ± 2.40 <0.001
Neutrophil (%) 47 ± 14 61 ± 14 65 ± 11 <0.001
Lymphocyte (%) 42 ± 13 29 ± 13 24 ± 9 <0.001
Monocyte (%) 9 ± 3 8 ± 3 8 ± 3 0.2
Platelet (×103/μL) 319 ± 111 266 ± 91 251 ± 75 0.002
CRP (mg/dL) 1.6 ± 2.9 3.8 ± 4.8 4.1 ± 4.1 0.03
ESR (mm/h) 40 ± 22 44 ± 20 46 ± 21 0.4
Seroconveter (n, %) ‡ 16 (55) 35 (43) 35 (43) 0.4
* P = 0.04, compared to the ≤2 y group
†Number of cases that had the duration of fever ≥7 days.
‡ Number of patients who showed negative on the initial examination, and converted to positive on the second examination by Serodia Myco 
II.Youn et al. BMC Pediatrics 2010, 10:48
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Table 2: Clinical and laboratory characteristics for the children with M. pneumoniae pneumonia according to the 
pneumonia pattern
Group Bronchopneumonia Segmental/Lobar P
(n = 96) (n = 95)
Clinical characteristics
Mean age (y) 4.6 ± 2.5 6.6 ± 3.0 <0.001
Male/Female 47/49 42/53
Duration of fever (d) 5.5 ± 2.8 6.5 ± 2.8 0.02
Hospitalization (d) 6.4 ± 1.7 7.3 ± 2.3 0.001
Laboratory findings
Haemoglobin (g/dL) 12.3 ± 0.9 12.0 ± 0.9 0.09
Leukocyte (×103//μL) 8.7 ± 4.9 7.4 ± 3.0 0.04
Neutrophil (%) 56 ± 14 65 ± 12 <0.001
Lymphocyte (%) 33 ± 13 25 ± 11 <0.001
Monocyte (%) 9 ± 3 8 ± 3 0.06
Lymphocyte count (/μL) 2700 ± 1700 1900 ± 1300 <0.001
Platelet (×103/μL) 283 ± 98 251 ± 80 0.02
CRP (mg/dL) 2.1 ± 2.3 5.1 ± 5.3 <0.001
ESR (mm/h) 39 ± 18 50 ± 21 0.001
Seroconveter (n,%) 36 (38) 50 (53) 0.04
Table 3: Clinical and laboratory findings according to the severity of the pulmonary lesions in the school-aged children (6-
14 years of age)
Groups Bronchopn Mild Severe P
(n = 25) (n = 33) (n = 23)
Clinical characteristics
Age (y) 8.0 ± 1.9 8.2 ± 2.1 9.1 ± 2.7 0.11
Duration of fever (d) 5.4 ± 2.8 6.0 ± 2.8 7.1 ± 2.6* 0.13
Hospitalization (d) 6.2 ± 1.9 6.7 ± 1.7 7.6 ± 2.4 0.04
Laboratory findings
Leukocyte (×103//μL) 6.9 ± 2.7 7.3 ± 2.3 6.9 ± 2.3 0.8
Neutrophil (%) 60 ± 11 66 ± 9 68 ± 12 0.053
Lymphocyte (%) 28 ± 9 23 ± 7 22 ± 11 0.08
Monocyte (%) 9 ± 4 8 ± 3 8 ± 2 0.5
Lymphocyte count (/μL) 1900 ± 800 1700 ± 700 1400 ± 600* 0.14
CRP (mg/dL) 2.2 ± 1.8 4.6 ± 4.8 5.4 ± 4.3 0.02
Seroconveter (n,%) 4 (16) 16 (49) 15 (65) 0.001
* P < 0.05 compared to the bronchopneumonia groupYoun et al. BMC Pediatrics 2010, 10:48
http://www.biomedcentral.com/1471-2431/10/48
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ervoirs of M. pneumoniae during MP epidemics [21,22],
the diagnosis of MP based on a single assay for IgM or a
PCR without serologic tests is inadequate for patient
selection.
Interestingly, among those aged ≥6 years, the group
with more severe pneumonia had a greater number of
seroconverters; i.e., patients with more severe pulmonary
lesions may be more likely to be sero-negative at presen-
tation. Because M. pneumoniae infection is controlled by
the adaptive immune reaction of the host, including anti-
bodies, patients with severe pneumonia may remain IgM-
negative longer in the early stage of MP. Indeed, the three
patients in the present series who had the most severe
clinical course were seroconverted at the third examina-
tion after 1 week.
The detection of cold agglutinins (IgM) is nonspecific
for M. pneumoniae infections; however, the titer of cold
agglutinins in other systemic infections (such as Epstein-
Barr virus and adenovirus infections) is rarely ≥1:64,
except in M. pneumoniae infections [23]. It is reported
that detection of cold agglutinins results in a higher sensi-
tivity and specificity for diagnosis of M. pneumoniae
infections when com pared with a serologic test for M.
pneumoniae [24,25]. According to the patient selection
policy employed in this study, nearly all patients among
the seroconverters were seroconverted in both serologic
assays; among the patients who were seroposive at pre-
sentation, 87% showed increased antibody titers ≥4-fold
in both serologic assays. Of the 1,083 patients with pneu-
monia or lower respiratory tract infections during this
study period, only 5 showed cold agglutinin changes
(≤1:64) without MAA changes. The detection rate of PCR
for M. pneumoniae in the present study (29%) was lower
than those in previous studies of children [26]. We
referred our respiratory samples to an external laboratory
for PCR and detection of viral antigens. Inconsistent sam-
ple delivery times, inadequate dilution of sample volume,
and other undetermined factors may (in part) have
affected our results.
It is recently reported that co-infection of M. pneumo-
niae with other bacterial and/or viral pathogens is not
rare [2,27,28]. In the present study, two cases of M. pneu-
moniae pneumonia were co-infected with viral infections
and there were no positive cases of bacterial blood cul-
ture. Because we did not perform extensive microbiologi-
cal testing of all the subjects, we cannot exclude the
possibility that some children might have had co-infec-
tion with other bacterial or viral pathogens. However, it is
assumed that our methodology (two serologic tests and
two examination times) would have reduced patient-
selection bias as much as possible. The clinical implica-
tions of mixed infections, compared with a sole agent,
remain unresolved [28].
All children in this study were treated with amoxicillin
with clavulanate and a macrolide (clarithromycin or rox-
ithromycin); 75% of the patients defervesced within 2
days and 83% of patients defervesced within 3 days after
initiation of antibiotic treatment. Of the patients with a
fever duration >4 days, 14 who were non-responsive to
antibiotics and had progressive pneumonia received
additional prednisolone treatment (1 mg/kg/day for 3-4
days, tapering within 1 week); these patients showed
rapid improvement of clinical and radiographic findings,
as previously observed [12]. The beneficial effects of sys-
temic corticosteroids on severe or fatal MP have been
well documented in children, adults, and experimental
animals [10-13,29]. A recent article reviewed clinical,
experimental, and pathologic studies for the notion of a
host immune response including cell-mediated immunity
in M. pneumonia infections [8].
Because the present study was performed during a
recent nationwide epidemic and the subjects were all
inpatients, our results might not reflect the exact epide-
miologic characteristics of M. pneumonia infections. Cli-
nicians can encounter intermittent endemic cases prior
to an epidemic with a 3-5 yr cycle, and our results may
help to prepare for coming MP epidemics and to under-
stand the clinical characteristics of MP.
Conclusion
The clinical phenotype of MP differs with age, with a lon-
ger period of fever, higher CRP, and more severe pulmo-
nary lesions observed in older children. The severity of
pulmonary lesions was associated with lower lymphocyte
count and higher sero-negativity of diagnostic IgM anti-
bodies at presentation. Short-term paired IgM serologic
test in the acute stage may assist in obtaining an early and
definitive diagnosis of MP and reduce bias in patient
selection. Further studies are required into the pathogen-
esis of M. pneumoniae infection.
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